OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has demonstrated significant progress in the clinical development of its drug candidate, urcosimod, which shows considerable potential for treating inflammatory eye diseases and chronic pain. The clinical trial results indicate that 67% of patients in the 0.05% urcosimod group experienced more than a 50% improvement in pain, significantly outperforming the 33% improvement seen in the placebo group, with marked reductions in pain scores noted as early as Week 4. These encouraging results position OKYO Pharma favorably within the biopharmaceutical sector, suggesting a promising outlook for the company's future developments and potential market impact.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year 2025, which translates to a loss of $0.12 per share, highlighting ongoing financial challenges and a lack of profitability. The clinical data indicates that patients in the 0.05% urcosimod group exhibited moderate to severe pain levels at baseline, suggesting a less favorable starting point compared to the placebo group, which could complicate the therapeutic's development and acceptance. Additionally, various risks, including potential failures in clinical trials, regulatory approval, and market penetration, further exacerbate the uncertainty surrounding the company's future performance.